Clobetasol Propionate

證據等級: L5

預測適應症: 7 個

Clobetasol Propionate: From Inflammatory Skin Disorders to Vulvar Inverted Follicular Keratosis

One-Sentence Summary

Clobetasol propionate is a super-potent (Class I/VII) topical corticosteroid widely used for severe inflammatory skin conditions such as psoriasis, lichen sclerosus, and chronic eczema. The TxGNN model predicts it may be effective for Vulvar Inverted Follicular Keratosis, but currently there are no clinical trials and no publications supporting this direction.

Quick Overview

Item	Content
Original Indication	Inflammatory skin disorders (no Taiwan regulatory approval data on file)
Predicted New Indication	Vulvar Inverted Follicular Keratosis
TxGNN Prediction Score	99.46%
Evidence Level	L5
Taiwan Market Status	Not marketed (未上市)
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known pharmacological class information, clobetasol propionate is a glucocorticoid receptor (GR) agonist. By activating GR, it suppresses the transcription factors NF-κB and AP-1, downregulating pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and inhibiting T-cell and mast cell activation. These effects account for its well-established efficacy in a broad range of inflammation-driven skin diseases.

Vulvar inverted follicular keratosis (IFK), however, is a benign epithelial tumor — essentially a squamous proliferative lesion histologically characterized by squamous eddies and endophytic growth. Its pathogenesis involves abnormal follicular epithelial differentiation rather than a sustained inflammatory cascade. There is no established mechanistic rationale for why glucocorticoid-mediated anti-inflammation would modify the course of this tumor.

The TxGNN model’s high prediction score (99.46%) most likely arises from broad node proximity between “vulvar skin disease” entities within the knowledge graph, rather than a genuine mechanistic connection between clobetasol and IFK. This is considered a probable false positive from the model, and no clinical or preclinical evidence exists to substantiate this repurposing direction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Vulvar inverted follicular keratosis is a benign, non-inflammatory epithelial tumor whose pathogenesis (abnormal follicular epithelial differentiation) has no biologically plausible connection to clobetasol’s anti-inflammatory glucocorticoid mechanism. With zero supporting clinical trials or literature, and a TxGNN score that likely reflects knowledge graph structural artifact rather than true mechanistic overlap, there is no basis to advance this candidate.

To proceed, the following is needed:

Obtain detailed MOA data from DrugBank API (DG002 remediation) to formally characterize the mechanistic gap
Download Taiwan FDA package insert PDF to assess warnings and contraindications (DG001 remediation — currently Blocking)
Conduct a literature review on IFK pathobiology to determine whether any glucocorticoid-responsive pathway (e.g., keratinocyte differentiation via GR) is plausibly involved
Evaluate preclinical in vitro data (e.g., effect of clobetasol on squamous epithelial cell lines) before any further clinical consideration

Note on higher-ranked evidence within this Evidence Pack: While the top TxGNN prediction (Rank 1) warrants a Hold, Rank 3 — Exanthem (disease) — carries an L1 evidence level with multiple completed Phase 3/4 RCTs directly testing clobetasol (e.g., NCT05010421, NCT01323673) and a “Proceed with Guardrails” recommendation. A separate targeted report on the Exanthem/Lichen Sclerosus/Lichen Planus indication cluster is strongly recommended as the primary repurposing opportunity for this drug.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.